8月15日,MIRXES-B(02629)发布公告,公司的间接全资附属公司MiRXES PTE.LTD.与印尼上市公司PTDIASTIKABIOTEKINDO签订了一份为期12个月的谅解备忘录,双方将就高发病率及高死亡率癌症的早期检测及诊断进行合作。主要合作活动包括在印尼销售和分销新型血源性循环microRNA及多组学癌症早期检测产品线,注册相关检测设备为医疗器械,共同开发及临床验证项目,以及提供开发和培训活动。
根据世界卫生组织2022年的资料,印尼每年新增癌症病例超过350,000宗,死亡率高达70%。通过与PTDIASTIKABIOTEKINDO的合作,公司可以利用其现有渠道迅速进入印尼市场,并借助印尼的本地化政策实现业务的全球扩展。董事会相信,此次合作是公司推动全球化战略及扩展至高潜力新兴市场的重要举措。
(文章来源:财中社)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.